A Systematic Review of the Use of Surgical Checklists in Transurethral Resection of Bladder Tumour
- PMID: 39518066
- PMCID: PMC11545027
- DOI: 10.3390/cancers16213626
A Systematic Review of the Use of Surgical Checklists in Transurethral Resection of Bladder Tumour
Abstract
Context: Surgical checklists have previously been shown to improve surgical quality and patient outcomes. However, their use in transurethral resection of bladder tumour (TURBT), one of the most commonly performed urological procedures, has yet to be explored in depth.
Objective: To evaluate the effect of surgical checklist implementation in TURBT on documentation quality, specimen quality, and oncological outcomes according to the existing literature. We then hope to develop an optimised TURBT checklist by identifying the most pertinent parameters for inclusion.
Evidence acquisition: A literature search using PubMed was performed to identify literature pertaining to the use of surgical checklists in the context of TURBT. A systematic review was then performed on the 41 identified studies, of which six were included in the final analysis.
Evidence synthesis: We explored three primary outcomes that arose from the literature, namely: (1) comprehensiveness of documentation; (2) resection quality; and (3) recurrence rates and recurrence-free survival (RFS). We found agreement in the literature that surgical checklist implementation does lead to an overall improvement in documentation. The effect of surgical checklists on resection quality and recurrence rates, however, was mixed in the literature, with some studies showing statistically significant improvements and others showing no significant change.
Conclusions: There are multiple benefits to surgical checklist implementation in TURBT procedures. We propose an optimised 14-item surgical checklist that should be implemented in every TURBT report to ensure sufficient information documentation for risk stratification and post-operative management.
Keywords: bladder cancer; checklist; systematic review; transurethral resection of bladder tumour.
Conflict of interest statement
I.D.D. and S.S. are unpaid Board Directors of the ANZUP cancer trials group. I.D.D. has been a member or chair of advisory boards for AstraZeneca, Bayer, BMS, Eisai, Ipsen, Janssen, Merck/Pfizer, MSD, Pio Therapeutics, Roche, and Xennials. All honoraria are invoiced by and paid directly to ANZUP Cancer Trials Group. I.D.D. is supported in part by an Australian NHMRC Investigator Grant (2016274). S.S. has been an adviser/speaker for Mundipharma, Ipsen, Abbvie and MSD (with honoraria donated directly into departmental research funds) and a paid adviser/speaker for Bristol Myers Squibb and Janssen.
References
-
- World Health Organization Cancer Fact Sheet. 2020. [(accessed on 8 September 2024)]. Available online: https://www.who.int/news-room/fact-sheets/detail/cancer.
-
- Australian Institute of Health and Welfare . Cancer Data in Australia. Australian Institute of Health and Welfare; Canberra, Australia: 2023.
Publication types
LinkOut - more resources
Full Text Sources